Evidence map›Paper›PMID 33212008›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2021

Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study.

Gagan Fervaha, Jason P Izard, Dean A Tripp, Nazanin Aghel, Bobby Shayegan, Laurence Klotz, Tamim Niazi, Vincent Fradet, Daniel Taussky, Luke T Lavallée and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Fear of cancer recurrence and PSA anxiety in patients with prostate cancer: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 16 institutions in 1 country.

Gagan FervahaSchool of Medicine, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Jason P IzardDepartment of Urology, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Dean A TrippDepartment of Urology, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Nazanin AghelDivision of Cardiology, Cardio-Oncology Program, McMaster University, Hamilton, ON, Canada.
Bobby ShayeganDivision of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada.
Laurence KlotzSunnybrook Health Sciences Centre, and Department of Surgery (Urology), University of Toronto, Toronto, ON, Canada.
Tamim NiaziDepartment of Oncology, McGill University, Montreal, QC, Canada.
Vincent FradetDivision of Urology, Department of Surgery, CHU de Québec-Université Laval, Quebec City, QC, Canada, and Centre de recherche du CHU de Québec-Université Laval, axe Oncologie, Quebec City, QC, Canada.
Daniel TausskyDepartment of Radiation Oncology, Centre Hospitalier de l'Université de Montréal-CHUM, Montreal, QC, Canada.
Luke T LavalléeDivision of Urology, Department of Surgery, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Robert J HamiltonPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, and Department of Surgery (Urology), University of Toronto, Toronto, ON, Canada.
Ian BrownNiagara Health, Niagara, ON, Canada.
Joseph ChinWestern University, London, ON, Canada.
Darin GopaulGrand River Regional Cancer Centre, Kitchener, ON, Canada.
Philippe D VioletteDepartment of Surgery and Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Margot K DavisDepartment of Cardiology, University of British Columbia, Vancouver, BC, Canada.
Sarah KarampatosThe Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
Jehonathan H PinthusDivision of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada.
Darryl P LeongThe Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.
D Robert SiemensDepartment of Urology, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
RADICAL PC Investigators
Queen's University · CAMcMaster University · CAPopulation Health Research Institute · CACentre Hospitalier de l’Université de Montréal · CAGrand River Hospital · CAImpact · CAMcGill University · CAOntario Clinical Oncology Group · CAPrincess Margaret Cancer Centre · CASunnybrook Health Science Centre · CAUniversité Laval · CAUniversity Health Network · CAUniversity of British Columbia · CAUniversity of Ottawa · CAUniversity of Toronto · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcross all cancer sites and stages, prostate cancer has one of the greatest median five-year survival rates, highlighting the important focus on survivorship issues following diagnosis and treatment. In the current study, we sought to evaluate the prevalence and predictors of depression in a large, multicenter, contemporary, prospectively collected sample of men with prostate cancer.

methodsData from the current study were drawn from the baseline visit of men enrolled in the RADICAL PC study. Men with a new diagnosis of prostate cancer or patients initiating androgen deprivation therapy for prostate cancer for the first time were recruited. Depressive symptoms were evaluated using the nine-item version of the Patient Health Questionnaire (PHQ-9). To evaluate factors associated with depression, a multivariable logistic regression model was constructed, including biological, psychological, and social predictor variables.

resultsData from 2445 patients were analyzed. Of these, 201 (8.2%) endorsed clinically significant depression. Younger age (odds ratio [OR] 1.38, 95% confidence interval [CI] 1.16-1.60 per 10-year decrease), being a current smoker (OR 2.77, 95% CI 1.66-4.58), former alcohol use (OR 2.63, 95% CI 1.33-5.20), poorer performance status (OR 5.01, 95% CI 3.49-7.20), having a pre-existing clinical diagnosis of depression or anxiety (OR 3.64, 95% CI 2.42-5.48), and having high-risk prostate cancer (OR 1.49, 95% CI 1.05-2.12) all conferred independent risk for depression.

conclusionsClinically significant depression is common in men with prostate cancer. Depression risk is associated with a host of biopsychosocial variables. Clinicians should be vigilant to screen for depression in those patients with poor social determinants of health, concomitant disability, and advanced disease.

Identifiers

PMID33212008
PMCPMC8195585
OpenAlexW3101761527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.